Prognostic Factors in Hodgkin's Disease

• Published in: Leukemia & lymphoma Vol. 45; no. 6; pp. 1133 - 1139
• Main Authors: Provencio, Mariano, España, Pilar, Millán, Isabel, Yebra, Miguel, Sánchez, Antonio C, de la Torre, Alejandro, Bonilla, Félix, Regueiro, Carlos A, de Letona, Juan Martínez L
• Format: Journal Article
• Language: English
• Published: United States Informa UK Ltd 01-06-2004; Taylor & Francis
• Subjects: Adult; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - metabolism; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Hodgkin Disease - diagnosis; Hodgkin Disease - mortality; Hodgkin Disease - therapy; Hodgkin's disease; Humans; Male; Neoplasm Staging; Prognosis; Prognostic factors; Remission Induction; Survival Rate; Treatment Outcome
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428190310001646022

Hodgkin's disease (HD) is a curable tumoral disease. However, there are groups of patients who suffer relapse and the identification of prognostic factors and the adaptation of treatments to individual risk is one the lines of investigation in this disease. A study was performed on 526 patients diagnosed of HD in our hospital between January 1967 and September 2001. An analysis was made of the most important variables in terms of both disease-free and overall survival. Overall survival in this series of patients was 94% at 2 years, 86% at 5 years, 76% at 10 years and 72% at 15 years. Median survival was 249 months. Factors influencing poor prognosis in the overall survival were: male gender (P < 0.0001), lymphocyte depletion (P < 0.0001), stages III and IV (P < 0.0001), B symptoms (P < 0.0001), spleen involvement at diagnosis (P = 0.003), no complete remission after first line treatment (P < 0.0001), and more than 30 years-of-age (P < 0.0001). Disease free survival was 83% at 2 years and 68% at 5 years although without reaching the mean follow-up. The disease free survival study revealed the following risk factors: male gender (P = 0.02), lymphocyte depletion (P < 0.0001), stages III and IV (P < 0.001), B symptoms (P < 0.001), extranodal or splenic involvement (P < 0.05), and no complete remission after first line treatment (P < 0.0001). The result of treatment optimization is that some factors that were considered to indicate a poor prognosis have disappeared, and that others which are useful have appeared and allow us to establish groups with differing risks of relapse and who could be candidates for differentiated treatments.